RED BIOTECHNOLOGY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Red Biotechnology Market Size and Trends

Global Red Biotechnology Market size is expected to reach US$ 1,513.22 Bn by 2030, from US$ 742.80 Bn in 2023, exhibiting a CAGR of 10.7% during the forecast period.

Global Red Biotechnology Market- Trends

• Growing Adoption of Personalized Medicine: The adoption of personalized medicine using biomarkers, genetics, and clinical data to customize treatments for patients is a rising trend benefiting red biotechnology. Companies are actively researching targeted biologics and precision immunotherapies that can selectively attack diseased cells based on a person's molecular profile. For example, Vitrakvi is a tissue-agnostic precision therapy for cancers with NTRK gene fusion. The future prospects of personalized medicine are immense, with the potential to make therapies more efficacious and safe.
• Strategic Collaborations on Novel Platform Technologies: In recent years, more cross-industry collaborations are being forged to combine complementary capabilities in bioprocessing, gene therapy, drug delivery, and manufacturing. Gilead-Galapagos, GSK-23andMe, Evotec-Bayer are some partnerships offering integrated expertise to fast-track innovation. Small biotech gain market access while big pharmas reduce risks and costs through synergy. Such mutually beneficial strategic tie-ups leverage novel platform technologies to accelerate biotherapeutics discovery and development.
• Rising Adoption of AI and Big Data: Pharma companies are increasing the use of big data analytics and AI to streamline biologics R&D. AI helps to identify new disease targets, predict clinical outcomes, design biologics, and simulate trials - compressing timelines and costs Data analytics improves biomanufacturing yields. Cloud-based informatics integrates workflows. The application of advanced computing can optimize biopharmaceutical processes and boost productivity.
• Shift to Low-Cost Biosimilar Drugs: Given the high costs of innovator biologics, there is a clear shift towards more affordable biosimilars which provide comparable efficacy and safety. The U.S. FDA approved 31 biosimilars between 2017 and 2021. Key biologic patents are also beginning to expire, opening the door for competition. Scaling biosimilar adoption can expand access to essential treatments while reducing pharmaceutical spending - a trend benefiting healthcare systems globally. Companies are strategizing to capitalize on the multi-billion dollar potential.